The North America molecular diagnostics market is expected to reach over USD 7.2 billion by 2024, according to a new report by Grand View Research, Inc. As a developed economy, North America has a well-equipped healthcare infrastructure. Moreover, the U.S. healthcare expenditure is projected to increase at a substantial rate over the forecast period.
Technological advancement in molecular diagnostic kits is expected to serve the as a primary driving force. Extensive R&D activities undertaken by the major companies for expansion of their product portfolio is another factor supporting growth. For instance, in 2015, a strategic collaboration was made between Sysmex Corporation and Laboratory Corporation in the field of blood-based molecular diagnostic tests to develop precision medicine in oncology.
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/north-america-molecular-diagnostics-market
Further Key Findings from the Report Suggest:
·
Reagents dominated the molecular diagnostics
market with revenue of over USD 1.0 billion in 2015, owing to increasing
R&D initiatives and as a result of discovery of novel biomarkers for
cancer. Moreover, the fastest growing segment over the forecast period is also
expected to be reagents, due to increasing adoption in the process of drug
discovery.
·
In 2015, the largest shareholder by test
location was central laboratories with around 60.0% share. The key attributes
included expansion of healthcare facilities and presence of multiple clinical
laboratory assays.
·
However, the point-of-care (PoC) segment is
estimated to witness the most lucrative growth over the forecast period owing
to development of fast and accurate diagnostic devices.
·
Infectious diseases contributed to the largest
market revenue in 2015, as a result of new product development in the field of
blood screening tests. HIV served as the largest market share rendering segment
among infectious diseases.
·
The oncology segment is expected to grow at a
lucrative double digit CAGR in the forecast period. This results from the high
prevalence of cancer and greater opportunities in the field of cancer
diagnostic tests for major players in North America.
·
On the basis of technology, polymerase chain
reaction (PCR) dominated the market with USD 1.2 billion in 2015, owing to
increasing applications of PCR in cancer tests
·
Sequencing is anticipated to be the fastest
growing technology over the forecast period due to introduction of
cost-effective and quick next-generation sequencing platforms for genetic
diseases, cancer, and other chronic disorders.
·
The U.S. held the major share of the market in
2015 attributable to its developed economy and greater level of awareness
amongst the population.
·
However, Canada is estimated to exhibit the
fastest growth in terms of CAGR, owing to increasing prevalence of lifestyle
diseases, such as cardiovascular diseases.
·
Some key players in the market include Abbott
Laboratories; Roche Diagnostics; Hologic, Inc. (Gen Probe); Novartis AG;
Bio-Rad laboratories, Inc.; Cepheid; Siemens Healthineers GmbH; Johnson &
Johnson Services, Inc.; Bayer AG; Alere; bioMérieux SA; Sysmex Corporation;
Becton, Dickinson and Company (BD); Danaher Corporation; Dako; and QIAGEN.
·
The strategies implemented by the participants
include innovations through introduction of devices providing quick test
results of blood samples and expansion to emerging markets.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the North American molecular diagnostics
market on the basis of product, test location, technology, application, and
country:North America Molecular Diagnostics Product Outlook (Market Revenue in USD Million, 2013 - 2024)
·
Instruments
·
Reagents
·
Others
North America Molecular Diagnostics Test Location Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
Point of care
·
Self-testing or OTC
·
Central laboratories
North America Molecular Diagnostics Technology Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
PCR
·
In-situ hybridization
·
Isothermal Nucleic Acid Amplification Technology
(INAAT)
·
Chips and microarrays
·
Mass spectrometry
·
Sequencing
·
Transcription-mediated amplification
·
Others
North America Molecular Diagnostics PCR, by segments Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
Multiplex PCR
·
Others
North America Molecular Diagnostics Application Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
Oncology
·
Pharmacogenomics
·
Infectious diseases
·
Genetic testing
·
Neurological diseases
·
Cardiovascular diseases
·
Microbiology
·
Others
North America Molecular Diagnostics Oncology, by Application Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
Breast Cancer
·
Prostate Cancer
·
Colorectal Cancer
·
Cervical Cancer
·
Kidney Cancer
·
Liver Cancer
·
Blood Cancer
·
Lung Cancer
·
Others
North America Molecular Diagnostics Infectious Disease, by
Application Outlook (Market Revenue in USD Million, 2013 - 2024)
·
Methicillin-resistant Staphylococcus aureus
(MRSA)
·
Clostridium difficile
·
Vancomycin-resistant enterococci
·
Carbapenem-resistant bacteria testing
·
Flu
·
Respiratory syncytial virus (RSV)
·
Candida
·
Tuberculosis (TB) and drug-resistant TB
·
Meningitis
·
Gastrointestinal panel testing
·
Chlamydia
·
Gonorrhea
·
HIV
·
Hepatitis C
·
Hepatitis B
·
Others
North America Molecular Diagnostics Genetic Testing, by Application
Outlook (Market Revenue in USD Million, 2013 - 2024)
·
Newborn screening
·
Predictive and presymptomatic testing
·
Others
North America Molecular Diagnostics Country Outlook (Market Revenue
in USD Million, 2013 - 2024)
·
U.S.
·
Canada
For press release of this report - http://www.grandviewresearch.com/press-release/north-america-molecular-diagnostics-market-analysis
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
